A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2 Positive Metastatic Breast Cancer
Interventions: DRUG: pyrotinib|DRUG: Lapatinib|DRUG: capecitabine
Sponsor: Jiangsu HengRui Medicine Co., Ltd.